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AbstrAct
Background: Acute kidney injury (AKI) in HIV-infected patients in sub-Saharan Africa is a common cause of hospi-
talisation and is associated with high morbidity and mortality. There is a paucity of comparative data regarding the 
outcomes of AKI in those patients with and without HIV infection from the African continent.
Methods: This was a single-centre retrospective study of all consecutive adult patients with AKI referred to the renal 
unit at Tygerberg Hospital for the period January 2015 to December 2016. The diagnosis of AKI required evidence 
of the following: a recent normal serum creatinine and/or normal kidney sizes on ultrasound examination and/or 
granular casts on urine microscopy. Kaplan–Meier curves and logistic regression were used to assess survival and 
identify factors predicting mortality. 
Results: We identified a total of 291 patients with AKI of whom 116 (40%) were HIV positive. HIV-positive patients 
had a mortality rate of 34.5% vs. 29.1% in the HIV-negative patients (P = 0.34). At hospital admission, HIV-positive 
patients had a higher admission serum creatinine (551 μmol/L vs. 190 μmol/L, P < 0.01). Of those who died, the 
HIV-positive patients were younger (41 vs. 52 years, P < 0.01), predominantly Black (87.5% vs. 23.5%, P < 0.01) and 
were mostly admitted to medical wards (92.5% vs. 41.2%, P < 0.01). There was no difference in mortality related to 
the use of renal replacement therapy (P = 0.50). Logistic regression identified mixed ancestry (OR 2.47, P = 0.02), 
HIV infection (OR 2.69, P < 0.01) and surgical ward admission (OR 2.05, P = 0.03) as predictors of death. 
Conclusions: In-hospital mortality of AKI was high, and HIV infection was associated with a greater risk of death. 
This may be the result of late presentation of both the AKI as well as the HIV infection.
Keywords: acute kidney injury; HIV; outcomes; mortality; South Africa.
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bAcKGrOUND
In 2015, there were 2.1 million new HIV infections 
worldwide, and a total of 36.7 million people living with 
HIV, half in sub-Saharan Africa [1]. Advances in treatment 
are largely responsible for a 26% decline in HIV-related 
deaths globally since 2010, from an estimated 1.5 million 
in 2010 to 1.1 million in 2015.
Despite these advances, South Africa continues to have 
the highest rate of HIV infection in the world, which has 
had a huge impact on the incidence of both chronic 
kidney disease (CKD) and acute kidney injury (AKI) [2]. 
In South Africa, there has been a 67% rise in deaths 
related to nephritis/nephrosis from 1999 to 2006 [3].
Causes of AKI in HIV-infected patients include hypo-
volaemia due to diarrhoeal disease, opportunistic infec-
tions and sepsis, nephrotoxicity due to drugs such as 
tenofovir and thrombotic microangiopathies [4,5].
In South Africa, AKI in HIV-infected patients remains a 
common cause of admission to emergency units. AKI 
independently predicts worse outcomes and is associated 
with additional costs on an already overburdened health-
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care system [6,7]. The reported incidence of AKI in HIV-
infected persons ranges from 2.7 to 5.9 per 100 person-
years with higher rates occurring in those recently diagnosed 
with HIV. The associated mortality is as high as 27–33% [8].
Risk factors for AKI include low CD4+ T-cell counts. 
Counts of < 200 cells/mm3 was one of the most important 
predictors of morbidity and mortality related to AKI in HIV-
infected patients. Decreasing levels of CD4+ T-cell counts 
have been associated with an increase in the incidence of 
AKI [9,10]. Other risk factors include AIDS-defining ill-
nesses, chronic liver disease due to hepatitis B and C, and 
nephrotoxicity related to highly active antiretroviral therapy 
(HAART) [4]. Many South African patients present late and 
usually develop AKI as a complication of diarrhoeal disease 
or opportunistic infections such as tuberculosis [11]. Drug-
induced nephrotoxicity related to agents such as tenofovir, 
rifampicin and amphotericin B are other common causes of 
AKI. Less common causes include thrombotic microangio-
pathies and the use of traditional remedies [12]. A mortality 
rate of 45.5% was observed among adult South African 
patients presenting with AKI who report the use of 
traditional medicines [13,14].
AKI is the most frequent organ failure in the setting of 
severe sepsis, with large multicentre studies suggesting that 
40% of all AKI in critically ill patients could be attributed to 
severe sepsis [15,16]. A local study reported that 43.6% of 
AKI in HIV-infected patients was due to sepsis [17]. An 
earlier study, conducted during the pre-HAART era at 
Tygerberg Hospital, reviewed AKI outcomes in an intensive 
care unit (ICU) over one year and identif ied only 3 of 
46 patients who were HIV positive. This likely reflected 
the local practice at the time not to admit HIV-infected 
patients to the ICU due to nihilism regarding the overall 
prognosis [18]. 
Morbidity and mortality have been demonstrated to be 
higher in those with HIV who develop AKI [8,19,20]. A 
study of the long-term consequences of AKI reported high 
rates of subsequent cardiovascular disease, end-stage renal 
disease and increased mortality [21]. In the developed 
world, the incidence of AKI and HIV-associated nephropathy 
(HIVAN) has decreased substantially as a result of early 
administration of HAART. 
Much work has been done regarding HIVAN and HIV-
related CKD; however, there remains a paucity of data 
regarding AKI and the outcomes of renal replacement 
therapy (RRT) in the HIV-infected as compared to HIV-
uninfected patients. In this paper we report on a cohort of 
patients with AKI at a tertiary hospital in South Africa and 
provide mortality data based on HIV serological status. 
MEtHODs
This was a retrospective, cohort study of patients with AKI 
admitted to Tygerberg Hospital from 1 January 2015 to 
31 December 2016. The hospital is a 1380-bed, public 
sector teaching hospital in Cape Town and provides 
secondary and tertiary level care to approximately 1.5 
million people in the Western Cape province of South 
Africa. It is one of two tertiary hospitals in the province 
responsible for providing acute and chronic adult dialysis 
services. The modality of dialysis most frequently employed 
is intermittent haemodialysis. Patients who are haemo-
dynamically unstable are offered slow, low-efficiency dialysis 
(SLED). Haemodialysis is initiated at the discretion of the 
attending nephrologist and in most cases this is when 
traditional indications such as refractory hyperkalaemia or 
pulmonary oedema have arisen.
This study included all adult patients (≥ 18 years) referred 
to the Division of Nephrology with AKI. The Kidney 
Disease: Improving Global Outcomes (KDIGO) criteria for 
AKI staging was not used because only 105 patients (36%) 
had information on baseline kidney function available. Most 
of the patients had community-acquired AKI and presented 
with established AKI at the time of referral. Urine output 
data were also not available for many of the patients. 
Therefore, the diagnosis of AKI was determined based on 
the following information: (1) where available, a normal 
serum creatinine concentration and an estimated glomerular 
filtration rate of > 60 mL/min/1.73 m2 in the preceding 3 
months and/or (2) normal kidney sizes by ultrasound 
examination (>100 mm in length) and/or (3) the docu-
mentation of granular casts on urine microscopy. Patients 
were excluded if they had CKD or evidence of glomerular 
disease. 
Data that were extracted from clinical f iles included 
demographics, AKI diagnosis, additional comorbidities, 
administration of HAART, use of renal replacement therapy 
versus conservative management, the ward to which the 
patient was admitted (medical versus surgical), and 
laboratory data including serum creatinine and CD4+ T-cell 
counts.
Patients were divided into two groups: HIV positive and 
HIV negative. These groups were further subdivided into 
those that did and did not receive RRT. Differences in 
mortality between these groups were compared as a 
primary endpoint.
All numerical data with a normal distribution were described 
using means ± standard deviations. Non-normal data were 
reported as medians and interquartile ranges (IQR). The 
chi-squared test was used to analyse mortality in different 
aKi in South african patients with HiV infection
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groups. Univariable and multivariable logistic regressions 
were used to identify predictors of death. The t-test was 
employed to compare the means of continuous data where 
the data had a normal distribution. Where data did not 
have a normal distribution, the Mann–Whitney U test was 
used. Statistical significance was set at a P value of < 0.05.
Permission to perform this study was granted by the Health 
Research Ethics Committee at Stellenbosch University 
(approval number S17/01/006) and was conducted in 
accordance with the Declaration of Helsinki.
rEsULts
A total of 291 cases of AKI were identified. Of these, 116 
(40%) were HIV positive. At baseline, the median age was 
39 years (IQR 32–46 years), and in the HIV-positive and 
HIV-negative groups it was 38 years (IQR 32–46 years) and 
42 years (IQR 29–56 years), respectively (P = 0.06). One 
hundred and forty-seven patients (51%) were female, with 
no significant difference between the groups (P = 0.27). 
More patients in the HIV-positive group were Black than in 
the HIV-negative group (90.5% versus 40.6%, respectively, 
P < 0.01). See Table 1. 
Approximately half (155 patients, 53%) of the patients had 
comorbid diseases. Non-communicable diseases were 
more common in HIV-negative cases. Hypertension 
occurred in 7.8% of HIV-positive patients as compared 
to 18.3% of HIV-negative patients (P = 0.01). More 
HIV-infected patients had a diagnosis of tuberculosis 
than those who were HIV-negative (19.0% versus 2.9%, 
respectively, P < 0.01).
Regarding baseline laboratory data, the overall median 
serum creatinine at admission was 240 μmol/L (IQR 114–
656 μmol/L). In the HIV-positive group, the median 
creatinine on admission was much higher at 552 μmol/L 
(IQR 173–837 μmol/L) than in the HIV-negative group 
at 190 μmol/L (IQR 104–416 μmol/L, P < 0.01). The 
overall median serum creatinine at the start of renal 
replacement therapy was 738 μmol/L (IQR 575–1112.5 
μmol/L), with the HIV-positive group having a median 
creatinine of 923 μmol/L (IQR 61–1221 μmol/L) as 
compared to the HIV-negative group of 722 μmol/L (IQR 
559–1044 μmol/L, P = 0.11). At hospital discharge, the 
overall median creatinine concentration was 120 μmol/L 
(IQR 83–181 μmol/L), with the HIV-positive group having 
a median value of 137 μmol/L (IQR 93–194 μmol/L) as 
compared to the HIV-negative group of 108.5 μmol/L (IQR 
77–169 μmol/L, P = 0.06). The median CD4+ T-cell count 
was 132 cells/mm3 in the HIV-positive group. See Table 1. 
The most common causes of AKI in the HIV-positive 
patients included pneumonia (27%) and diarrhoeal disease 
(22%), whereas pneumonia (14%), rhabdomyolysis (19%) 
and obstetric (11%) aetiologies predominated in the HIV-
negative patients. All the patients with cardiac failure were 
HIV negative. 
The leading category of AKI was ischaemic acute tubular 
necrosis (ATN) (46%), followed by septic ATN (38%). 
More HIV-positive patients had septic ATN than the HIV-
negative group (53% versus 27%, P < 0.01). Other causes 
of AKI included toxic ATN (13%), acute tubulointerstitial 
nephritis (3%) and pre-renal azotaemia (0.7%).
A total of 67 (23%) patients received RRT of whom 19 
(16%) were HIV positive and 48 (27%) were HIV negative 
(P = 0.03). The most common indication for RRT initiation 
was hyperkalaemia. 
Regarding the primary outcome of in-hospital mortality, 
the overall number of deaths was 91 (31%) with 40 (35%) 
from the HIV-positive group and 51 (29%) from the HIV-
negative group (P = 0.34, see Figures 1A and 1B). The 
overall median age was 45 years (IQR 35–54 years), while 
for the HIV-positive patients it was 41 years (IQR 34–47 
years) as compared to 52 years (IQR 37–60 years) for the 
HIV-negative group (P < 0.01). See Table 2.  
Overall mortality was higher in males (53/91, 58%) and 
more males in the HIV-positive group died than in the 
HIV-negative group (73% versus 47%, P = 0.02). Black 
patients represented approximately half of the overall 
mortality with the overwhelming majority being HIV 
positive (88% versus 24%, P < 0.01). The mortality rate 
was highest for those patients in the medical wards (58 
patients, 64%) with most HIV positive patients (93%) dying 
in the medical wards as compared to most HIV-negative 
patients dying in the surgical wards (57%, P < 0.01). There 
was no difference in survival between those who received 
and those who did not receive RRT. See Figure 1C.
Seventy-four (64%) of the HIV-positive group had a CD4+ 
T-cell count < 200 cells/mm3. This group had higher 
mortality than HIV-positive patients, with a CD4+ T-cell 
count of > 200 cells/mm3 (P = 0.01) (Table 3). Sixty-seven 
patients were on HAART of whom 22 (33%) died; 48 
were not receiving treatment of whom 18 (38%) died.
Univariate logistic regression analysis identified age, male 
sex and mixed ancestry as predictors of death; however, 
multivariate logistic regression analysis revealed mixed 
ancestry, being HIV positive and admission to surgical 
wards as predictors of mortality. See Table 4.
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aKi in South african patients with HiV infection
table 1. Baseline characteristics of HiV-positive and HiV-negative patients with aKi.
Baseline characteristics alln = 291
HiV+
n = 116
HiV–
n = 175 P value
Demographic data
Age, median (IQR) 39 (30–53) 38 (32–46) 42 (29–56) 0.06
Female, n (% of group) 147 (50.5) 54 (46.6) 93 (53.1) 0.27
Ethnicity, n (% of group)
  Black 176 (60.5) 105 (90.5) 71 (40.6) < 0.01
  White 28 (9.6) 2 (1.7) 26 (14.9) –
  Mixed ancestry 87 (29.9) 9 (7.7) 78 (44.5) –
Comorbid diseases, n (% of group)
Hypertension 41 (14.1) 9 (7.8) 32 (18.3) 0.01
Diabetes mellitus 31 (10.7) 10 (8.6) 21 (12.0) 0.36
Tuberculosis (pulmonary and extrapulmonary) 27 (9.3) 22 (19.0) 5 (2.9) < 0.01
Other* 56 (19.2) 10 (8.6) 46 (26.3) < 0.01
laboratory data, median (iQR)
Admission creatinine (μmol/L) 240 (114–656) 551.5 (173.5–837) 190 (101–416) < 0.01
Creatinine at RRT initiation (μmol/L) 738 (575–1113) 923 (691–1221) 722 (559–1044) 0.11
Creatinine at hospital discharge 120 (83–181) 137 (93–194) 108.5 (77–169) 0.06
CD4+ T-cell count, n=115 – 132 (47–292) N/A –
Causes of aKi, n (% of group)
Pneumonia 55 (18.9) 31 (26.7) 24 (13.7) < 0.01
Rhabdomyolysis 38 (13.1) 5 (4.3) 33 (18.9) –
Obstetric 23 (7.9) 3 (2.6) 20 (11.4) –
Urosepsis 18 (6.2) 11 (9.5) 7 (4.0) –
Diarrhoea 42 (14.4) 25 (21.6) 17 (9.7) –
Cardiac failure 10 (3.4) 0 (0) 10 (5.7) –
Drugs/toxins 19 (6.5) 9 (7.8) 10 (5.7) –
Pancreatitis 8 (2.7) 1 (0.9) 7 (4.0) –
GSW 7 (2.4) 0 (0) 7 (4.0) –
Ruptured AAA 2 (0.7) 0 (0) 2 (1.1) –
Bowel ischaemia 3 (1.0) 0 (0) 3 (1.7) –
Bowel perforation 4 (1.4) 0 (0) 4 (2.3) –
Other# 59 (20.3) 29 (25.0) 30 (17.1)
type of aKi, n (% of group)
Septic ATN 110 (37.8) 62 (53.4) 48 (27.4) < 0.01
Ischaemic ATN 133 (45.7) 40 (34.5) 93 (53.1) –
Toxic ATN 37 (12.7) 7 (6.0) 30 (17.1) –
ATIN 9 (3.1) 7 (6.0) 2 (1.1) –
Pre-renal AKI 2 (0.7) 0 (0.0) 2 (1.1) –
Ward, n (% of group)
Medical 182 (62.5) 99 (85.3) 83 (47.4) < 0.01
Surgical 109 (37.5) 17 (14.7) 92 (52.6) –
indications for RRt, n (% of group)
Hyperkalaemia 28 (9.6) 5 (4.3) 23 (13.1) 0.01
Metabolic acidosis 2 (0.7) 1 (0.9) 1 (0.6) 1.00
Pulmonary oedema 18 (6.2) 6 (5.2) 12 (6.9) 0.56
Fluid overload 13 (4.5) 5 (4.3) 8 (4.6) 0.92
Encephalopathy 7 (2.4) 5 (4.3) 2 (1.1) 0.12
Pericarditis 1 (0.3) 1 (0.9) 0 (0.0) 0.40
Offered RRt, n (% of group)
Yes 67 (23.0) 19 (16.4) 48 (27.4) 0.03
No 224 (77.0) 97 (83.6) 127 (72.6) –
Abbreviations: HIV, human immunodeficiency virus; RRT, renal replacement therapy; AKI, acute kidney injury; ATN, acute tubular necrosis; ATIN, acute tubulointerstitial nephritis; 
GSW, gunshot wound; AAA, abdominal aortic aneurysm. *Other comorbidities: carcinoma, liver failure, alcohol dependence, chronic obstructive pulmonary disease, asthma, 
chronic hepatitis B, gout, systemic lupus erythematosus, rheumatoid arthritis, interstitial lung disease, cerebrovascular accident, mitral valve replacement, rheumatic heart 
disease, aortic dissection, deep vein thrombosis, abdominal aortic aneurysm, meningioma, peptic ulcer disease, major depressive disorder, atrial fibrillation, pulmonary embolism, 
epilepsy, gastroesophageal reflux disease, mycobacterium other than tuberculosis, schwannoma, panhypopituitarism, peripheral vascular disease, hypothyroidism. #Other causes 
of AKI: necrotizing fasciitis, meningitis, peptic ulcer perforation, cholecystitis, contrast nephropathy, compartment syndrome, diabetic ketoacidosis, burn wounds, acute liver 
failure and sepsis of unknown origin.    
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DIscUssION
We found a high overall in-hospital mortality of 31%, 
whereas others have reported lower mortality rates. Nash 
et al. focused on hospital-acquired AKI and found an overall 
mortality rate of 19.4% [22]. Liangos et al. reported a 
mortality rate of 21.3% in hospitalized patients with AKI, 
which was nearly 10 times greater than patients without 
AKI [23]; Wang et al. documented an in-hospital mortality 
in incident AKI patients of only 10% [24]. These studies 
had relatively lower mortality rates despite patients being 
older, having more non-communicable diseases and being 
mostly HIV uninfected. For patients who developed 
hospital-acquired AKI, the earlier identification and initiation 
of treatment may have resulted in improved outcomes. 
Most of the patients in our study had community-acquired 
AKI and late presentation may have contributed to poorer 
outcomes.    
We found no difference in crude mortality between HIV-
positive and HIV-negative patients. Few studies have 
reported direct comparisons. A 2012 systematic review 
concluded that there were insufficient data for this pur-
pose [25]. More recently, some studies from South Africa 
have reported on these outcomes. One of these studies 
compared the outcomes of AKI in critically ill adult patients 
treated with continuous RRT and reported very high  90-
day mortality rates in the HIV-positive patients (60% vs. 
10%) [26]. This was thought to be related to late 
presentation. The lower mortality in our study is probably 
due to the inclusion of patients who had AKI but recovered 
kidney function without the need for dialysis, the inclusion 
of less critically ill patients and our focusing on only in-
hospital mortality. A Johannesburg study reported slightly 
higher in-hospital mortality rates than in our study [27]. 
This study included patients with chronic kidney disease, 
which may have affected mortality. We identified HIV as an 
independent predictor of death. The reason for this is 
uncertain but may be related to late presentation of both 
the AKI as well as the HIV infection. 
We found no difference in mortality related to RRT. A 
study of HIV-positive patients with AKI requiring dialysis 
noted that patients who died had lower CD4+ counts, 
fewer dialysis days as well as shorter length of hospital stay 
relative to those who recovered kidney function or 
remained dialysis-dependent [17]. Our findings support the 
conclusions of others [17,27] that HIV-infected patients 
with AKI should be considered for acute dialysis support 
because their outcomes are similar to those of HIV-negative 
patients with AKI.
Most of the HIV-positive patients who died were relatively 
young, Black, male, predominantly admitted to medical 
wards and had septic AKI. These findings were nearly 
identical to those documented by other South African 
studies [17,26,27]. The median CD4+ count at baseline 
was 132 cells/mm3, indicating late HIV diagnosis. A low 
CD4+ count is known to be a strong risk factor for the 
development of AKI as well as death [9,17]. Our study also 
found a higher mortality when CD4+ counts were less 
than 200 cells/mm3. 
aKi in South african patients with HiV infection
Figure 1.  survival analysis for all patients with AKI 
and by HIV status and need for renal replacement 
therapy.  a, Overall survival. B, Comparison of survival 
between HiV-positive and HiV-negative patients (log-rank, P 
= 0.22). C, Comparison of survival between HiV-positive and 
HiV-negative patients receiving RRt (log-rank, P = 0.46). 
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Mixed ancestry, HIV-positive status and surgical ward 
admission were independent predictors of death. Mixed 
ancestry as a predictor was probably a reflection of this 
ethnic group constituting nearly half of the Western Cape 
population [28]. Since most of the HIV-positive patients 
who died had CD4+ counts less than 200 cells/mm3, it is 
likely that the late diagnosis of infection was a major factor 
contributing to this risk. Most of the surgical patients who 
died were HIV negative; however, these cases were older, 
had more comorbidities, and were predominantly admitted 
to the surgical ICU. AKI in this sub-group of critically ill 
patients was associated with poor outcomes.          
We found that ATN was the most common cause of AKI 
with septic ATN as the dominant cause in the case of HIV-
infected patients whereas ischaemic ATN predominated in 
the HIV-negative patients. This finding was comparable to 
other studies [17,27,29]. Prakash et al. reported that 53% 
of their HIV patients had pre-renal azotaemia at presenta-
tion [29], whereas none of our HIV patients had this 
condition. Many of our patients’ first contact with medical 
aKi in South african patients with HiV infection
table 2.  Mortality in HiV-positive and HiV-negative patients with aKi.
all HiV+ HiV– P value
Overall mortality, n (% of group) 91 (31) 40 (35) 51 (29) 0.34
Variables in patients who died
Age, median (IQR) 45 (35–54) 41 (34–47) 52 (37–60) < 0.01
Sex, n (% of group)
Male 53 (58.2) 29 (72.5) 24 (47.1) 0.02
ethnicity, n (% of group)
Black 47 (51.6) 35 (87.5) 12 (23.5) < 0.01
White 12 (13.2) 2 (5.0) 10 (19.6) –
Mixed 30 (33.0) 2 (5.0) 28 (54.9) –
Unknown 2 (2.2) 1 (2.5) 1 (2.0) –
Ward admission, n (% of group)
Medical 58 (63.7) 37 (92.5) 21 (41.2) < 0.01
Surgical 32 (35.2) 3 (7.5) 29 (56.9) –
OBGYN 1 (1.1) 0 (0) 1 (2.0) –
Medical ICU only 17 (18.7) 7 (17.5) 10 (19.6) 0.06
Surgical ICU only 24 (26.4) 3 (7.5) 21 (41.2) –
Cause of atn, n (% of group)
Septic 49 (53.8) 25 (62.5) 24 (47.1) 0.04
Ischaemic 33 (36.3) 13 (32.5) 20 (39.2) –
Toxic 6 (6.6) 0 (0) 6 (11.8) –
Received RRt, n (% of group)
No 65 (71.4) 30 (75.0) 35 (68.6) 0.46
Yes 26 (28.6) 10 (25.0) 16 (31.4) –
Abbreviations: HIV, human immunodeficiency virus; IQR, interquartile range; ICU, intensive care unit; OBGYN, obstetrics and gynaecology; ATN, acute tubular necrosis; RRT, 
renal replacement therapy.
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services is at their peripheral hospitals where treatment, 
such as a fluid challenge, is initiated. Only if the response to 
therapy is judged as poor, or the referring physician 
anticipates that RRT may soon be needed, are patients 
referred to our facility for possible dialysis. Therefore, many 
patients with pre-renal azotaemia do not reach our facility 
because they recover kidney function at their peripheral 
hospitals and are not referred. 
The serum creatinine concentration at the time of 
presentation was much higher in the HIV-positive patients. 
Difficulty in accessing healthcare facilities, delays in diag-
nosis and transfer to tertiary centres are some of the issues 
that contribute to late presentation. The median serum 
creatinine concentration at initiation of RRT was not 
different between the HIV-positive and HIV-negative 
groups. Arendse et al. reported a pre-dialysis serum 
creatinine value of 998 μmol/L, which was similar to our 
patients at the time dialysis was started [17]. In general, due 
to resource constraints, the initiation of acute dialysis in the 
South African public sector is usually delayed until more 
traditional indications have evolved. This practice may vary 
within centres, from one nephrologist to the next, as well 
as between the public and private healthcare sectors.   
LIMItAtIONs
This was a single-centre, retrospective study. We could not 
define AKI using more contemporary staging criteria such 
as the KDIGO or Acute Kidney Injury Network (AKIN) 
criteria because most of the patients included did not 
have baseline kidney function available and urine output 
was not well monitored. Only referrals to our service were 
assessed. Patients who were not referred may either have 
died or had mild injury that did not require referral. This 
may have influenced mortality outcomes. Also, we were 
unable to score the severity of the illness at presentation 
and therefore were unable to comment on the effect 
that this may have had on outcomes. Finally, since this 
study was conducted in a public sector hospital, mortality 
outcomes may differ from those of the private sector due 
to differences in case mix as well as variations in practice.
cONcLUsIONs
In patients with AKI, there was no difference in crude 
mortality rates based on HIV status or the need for RRT. 
However, HIV infection was associated with increased 
mortality. This may be related to late presentation of both 
the HIV diagnosis as well as the AKI.
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table 3.  Mortality in HiV-positive patients based on CD4+ 
cell count and use of HaaRt.   
all HiV+ P value
CD4+ count (cells/mm3) n = 116 (%)
< 200 74 (63.8) 32 (27.6) 0.01
≥ 200 42 (36.2) 8 (6.9)
HaaRt n = 115 (%)
Yes 67 (58) 22 (33) 0.65
No 48 (42) 18 (38)
Abbreviations: HIV, human immunodeficiency virus; HAART, highly active anti-
retroviral therapy.
table 4.  Predictors of mortality using univariable and 
multivariable logistic regression.   
Univariable logistic 
regression
Odds 
ratio P value 95% Ci
Age 1.02 < 0.01 1.01–1.04
Male sex 1.70 0.04 1.02–2.80
Ethnicity (reference Black)
  White 2.05 0.08 0.91–4.67
  Mixed ancestry 1.76 0.047 1.00–3.06
HIV-positive 1.27 0.34 0.77–2.11
Surgical ward 1.60 0.10 0.92–2.79
Multivariable logistic 
regression
Age 1.01 0.20 0.99–1.03
Male sex 1.22 0.47 0.71–2.11
Ethnicity (reference Black)
  White 2.28 0.10 0.84–6.16
  Mixed ancestry 2.47 0.02 1.18–5.15
HIV-positive 2.69 < 0.01 1.28–5.61
Surgical ward 2.05 0.03 1.09–3.96
Abbreviation: HIV, human immunodeficiency virus. 
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